Feldan Therapeutics
PrivateLast Round
Grant
Mar 12, 2026
Total Funding Raised
$52.77M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Feldan Therapeutics operates in Healthcare & Life Sciences and is based in Canada. Its latest recorded funding round was a Grant round in March 2026.
Feldan Therapeutics is a biopharmaceutical company specializing in the development of innovative treatments through advanced intracellular delivery technologies that enhance the safe and efficient transport of therapeutic compounds into cells.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Feldan Therapeutics Comparables
Compare Feldan Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Permeasis Therapeutics | 85% | |
| iDEL Therapeutics | 79% | |
| NanoSyrinx | 78% |
For institutional investors. Book with your work email.
Feldan Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Mar 12, 2026 | ||||
| Grant | Sep 23, 2025 | ||||
| Series B | Apr 16, 2025 | ||||
| Strategic | Feb 18, 2025 | ||||
| Series B Extension | Sep 4, 2024 | ||||
Grant | Aug 28, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Feldan Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Canadian Institutes of Health Research | Grant |
| Investissement Québec | Series B Extension, Series B |
| Investissement Québec | Series B, Strategic, Series B Extension |
| Fonds de solidarité FTQ | Strategic, Series B Extension |
| Consortium Québécois sur la découverte du médicament | Grant |
| Future Standard | Series B |
| Zynext Ventures | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 40% MoM.
- Jul 25, 2026
Monthly visitors grew 45% MoM.
For institutional investors. Book with your work email.
Feldan Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Feldan Therapeutics's valuation, stock price, and market status.
Is Feldan Therapeutics a public or private company?
Feldan Therapeutics is a private company.
What is the current stock price of Feldan Therapeutics?
Feldan Therapeutics is a private company, so its shares have no public market price. Caplight tracks Feldan Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Feldan Therapeutics worth (valuation)?
Valuation information for Feldan Therapeutics is not publicly available.
Can I buy Feldan Therapeutics stock?
Feldan Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Feldan Therapeutics's last funding round?
Feldan Therapeutics's most recent funding round was Grant on March 12, 2026.
Who are the main investors in Feldan Therapeutics?
Key investors in Feldan Therapeutics include Investissement Québec, Fonds de solidarité FTQ, Genesys Capital.
Will Feldan Therapeutics IPO soon?
No public IPO plans have been announced for Feldan Therapeutics.
How can I track Feldan Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Feldan Therapeutics's shares on secondary markets.